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ABSTRACT 
Objective: To evaluate drug therapy problems in asthma patients visiting a secondary and tertiary hospital in South-Eastern Nigeria. 
Methods: This study was a retrospective, cross-sectional analyses of the medical records of adult asthmatic patients receiving care in two hospitals 
in Enugu State, within a 15-year period. The Pharmaceutical Network Care Europe (PCNE) tool version 6.2 was used to assess drug therapy 
problems. The IBM Statistical Product for Services Solution (SPSS) version 20.0 was used for analysis. For all results, P ≤ 0.05 was considered 
statistically significant. 
Results: Majority of the patients were below 60 y old (81.2%); female (68.8%) and were on more than two drugs (95.3%). Majority of the identified 
drug therapy problems (DTPs) were adverse reactions (65.7%). The inappropriate drug combination was the major cause of DTPs (65.6%). Only 
about 23.4% of the intervention outcomes were known. University of Nigeria Teaching Hospital (UNTH) had more interventions (35.9%) than 
Medical Centre (8.0%) (χ2 = 6.323; df = 1; **P = 0.012); and more of the outcomes of their interventions known (38.5%) compared to Medical Centre 
(0.0%) (χ2 = 12.559; df = 1; **P ˂ 0.001). 
Conclusion: Adverse reactions and inappropriate drug selection were the major identified DTPs and major cause of DTPs, respectively. Most DTPs 
had no interventions. The documented interventions included stopping of the drugs, change of drugs or dosage, change of instructions for use and 
starting of new drugs. Most interventions had unknown outcomes. UNTH had more interventions with known outcomes than the University of 
Nigeria Medical Centre. 
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Asthma is a global health problem that imposes a substantial burden 
on patients, their families, and communities [1]. It affects an estimated 
300 million individuals worldwide. Asthma affects all age groups, with 
increasing prevalence in many developing countries [2]. In Africa, 
there is a paucity of data concerning the management pattern and 
burden of asthma [3]. Asthma is a serious burden in low-and-middle-
income countries [4]. According to the former National President of 
the Nigerian Thoracic Society; no fewer than 15 million Nigerians are 
suffering asthma, tuberculosis and other chest-related diseases [5]. 
This high number of Nigerians suffering from asthma and other chest 
diseases were attributed to lack of preventive measures. There is a 
high prevalence of asthma among Nigerian adolescents and adults 
compared with regional and global averages [6]. 
A drug therapy problem (DTP) is any undesirable event experienced 
by a patient that involves, or is suspected to involve drug therapy, and 
that interferes with achieving the desired goals of therapy and 
requires professional judgment to resolve [4]. DTPs are the clinical 
domain of the pharmaceutical care practitioner. The purpose of 
identifying drug therapy problems is to help patients achieve their 
goals of therapy and realize the best possible outcomes from drug 
therapy. 
The objective of this study was to assess drug therapy problems 
among adult asthmatic patients’ attending respiratory clinics in two 
hospitals in south-eastern Nigeria. 
MATERIALS AND METHODS 
Study design and study site 
This study was a retrospective, cross-sectional analysis of the 
medical records of adult asthmatic patients receiving care in two 
hospitals in Enugu State, within a 15 y period (January 1, 2001 to 
December 31, 2015). 
The University of Nigeria Teaching Hospital (UNTH), Ituku-Ozalla; a 
tertiary health institution and the University of Nigeria Medical 
Centre (UNMC); a secondary health institution were utilized for the 
study. 
Eligibility criteria 
The study population included the folders of all adult patients with 
confirmed diagnosed asthma within the study period (January 1, 
2001, to December 31, 2015); patients that were on asthma drug 
therapy within the study period; patients that were within the ages 
of 18 and above with available medical records. Only folders from 
UNTH and UNMC were utilized for the study. 
Data collection 
The data were collected from the patients` medical records using the 
Pharmaceutical Care Network Europe (PCNE) Classification tool 
Version 6.2 [7]. For each of the medical records, the DTPs 
experienced within 3 y from discharge or within three 3 y from last 
clinic visit were identified. The demographic information such as age 
and gender were recorded. Other data recorded were the drugs 
implicated in the therapy problems, type of DTP, the cause of DTP, 
type of intervention and the outcome of the intervention. 
The PCNE V 6.2 has 4 primary domains for problems, 8 primary 
domains for causes and 5 primary domains for interventions. On a 
more detailed level, there are 9 grouped sub-domains for problems, 37 
grouped sub-domains for causes and 17 grouped sub-domains for 
interventions. The sub-domains are explanatory for the principal 
domains. 
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Data were entered and analyzed using the IBM Statistical Product 
for Services Solution (SPSS) Statistics for Windows, Version 20.0 
(IBM Corp, Version 20.0, Armonk, NY, USA). Descriptive statistics 
were used to summarize data. The Pearson chi-square test was used, 
where applicable, to show the association between variables. For all 
results, p-value ≤ 0.05 was considered statistically significant.  
Ethical approval 
Ethical approval was obtained from the Health Research and Ethics 
Board committee of each hospital used for the survey 
(NHREC/05/01/2008B-FWA00002458-1RB00002323). 
RESULTS 
A total of 64 medical records of patients with confirmed diagnosis of 
asthma were reviewed and assessed for DTPs. More than half of the 
patients were below 60 y old (52, 81.2%), out of this 44 were female 
(68.8%). About 95.3% of the patients were taking more than two 
drugs. See table 1 for more details.  
Majority of the identified drug therapy problems were adverse 
reactions (65.7%), fig. 1. 
The combination of artemether-lumefantrine and vitamin c, as well 
as aminophylline and hydrocortisone, were responsible for more 
than a quarter of the drug therapy problems, table 2. 
Table 3 shows that inappropriate drug combinations were the major 
cause of drug therapy problem (65.6%).  
About three-quarter of the drug therapy problems had no 
documented interventions, table 4. 
Of the few interventions documented, only about 23.4% had known 
intervention outcomes, table 5.  
UNTH had more interventions (35.9%) than Medical Centre (8.0%), 
table 6. 
UNTH had more of the outcomes of their interventions known 
(38.5%) compared to Medical Centre (0.0%), table 7. 
 
Table 1: Demographic characteristics/drug details 
Variables n (%) 
Age  
18–29 18 (28.1) 
30–39 14 (21.9) 
40–59 20 (31.2) 
≥ 60 12 (18.8) 
Gender  
Male 20 (31.2) 
Female 44 (68.8) 
Type of Medicine  
Prescription 58 (95.1) 
OTC 3 (4.9) 
Hospital Visit  
New 42 (65.6) 
Refill 22 (34.4) 
Number of Drugs Taken  
0–2 3 (4.7) 
3–6 34 (53.1) 
≥ 7 27 (42.2) 
Institution  
UNTH 39 (60.9) 
UNN Medical Centre 25 (39.1) 
 
Table 2: Drugs involved with the identified drug therapy problems 
Name of medication Drug therapy problem n (%) 
Azithromycin+Antacid Absorption of Azithromycin is reduced by Antacid 1 (1.9) 
Azithromycin+Digoxin Plasma concentration of Digoxin is increased by Azithromycin 3 (5.6) 
Salbutamol Prescription error (dosage missing) 1 (1.9) 
Aminophylline Over-dose for indication 1 (1.9) 
Antacid Constipation 1 (1.9) 
Aminophylline+Ciprofloxacin Plasma concentration of Aminophylline is increased by Ciprofloxacin 4 (7.5) 
Aspirin, 75 mg Triggers bronchospasm  1 (1.9) 
Methyldopa+Furosemide Enhanced hypotensive effect when Furosemide is given with Methyldopa 1 (1.9) 
IV Hydrocortisone Prescription error (dosage missing) 1 (1.9) 
Aminophylline+Cimetidine Cimetidine inhibits metabolism of Aminophylline (Increased plasma concentration) 2 (3.7) 
Aminophylline+Hydrocortisone Plasma concentration of Aminophylline is increased by Hydrocortisone 9 (16.7) 
Artesunate+Vitamin C Vitamin C inhibits the oxidation of Artemisinin derivatives 1 (1.9) 
Aminophylline+Erythromycin Plasma concentration of Aminophylline is increased by Erythromycin 5 (9.3) 
Artemether/lumefantrine+Vitamin C Vitamin C inhibits the oxidation of Artemisinin derivatives 11 (20.4) 
Methyldopa No direction for use 1 (1.9) 
Methyldopa+Lisinopril Enhanced hypotensive effect when Lisinopril is given with Methyldopa 1 (1.9) 
Diclofenac Triggers bronchospasm 3 (5.6) 
IM Metamizole Triggers bronchospasm and has potential haematologic toxicity 2 (3.7) 
Cimetidine+Metronidazole Absorption of oral Metronidazole is inhibited by Cimetidine 1 (1.9) 
Dihydroartemisinin/Piperaquine+Vitamin C Vitamin C inhibits the oxidation of Dihydroartemisinin 2 (3.7) 
Artemether/lumefantrine+Cimetidine Cimetidine inhibits the metabolism of Artemether/lumefantrine 1 (1.9) 
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Fig. 1: Type of drug therapy problem 
 
Table 3: Cause of drug therapy problems 
Variables n (%) 
Drug Selection  
Inappropriate drug 9 (14.1) 
No indication for drug 1 (1.6) 
Inappropriate combination 42 (65.6) 
Too many drugs for indication 2 (3.1) 
More cost-effective drugs available 2 (3.1) 
Synergistic or preventive drug required 4 (6.2) 
New indication presented 1 (1.6) 
Dose Selection  
Drug dose too high 1 (1.6) 
No therapeutic drug monitoring 2 (3.1) 
Pharmacokinetic problem 2 (3.1) 
Drug Use Process  
Drug under used or administered 3 (4.7) 
The wrong drug is taken or administered 6 (9.4) 
Prescribing error (information wrong or missing) 6 (9.4) 
Patient  
Patient forgets to take drug 2 (3.1) 
Patient uses unnecessary drug 1 (1.6) 
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Table 4: Type of intervention 
Variables n (%) 
No intervention 48 (75.0) 
Prescriber level  
Prescriber asked for information 1 (1.6) 
Drug level  
Drug Changed to:   
Aminophylline+Salbutamol 1 (1.6) 
Hydrochlorothiazide 1 (1.6) 
Seretide+Ventolin 2 (3.1) 
Tabs. Augmentin 1 (1.6) 
Salbutamol 1 (1.6) 
Cefixime 1 (1.6) 
Dosage changed to:   
Aminophylline 100 mg daily 1 (1.6) 
Instructions for use changed to:   
IV hydrocortisone 100 mg thrice daily for 7 d 2 (3.1) 
Drug Stopped:   
Azithromycin+Digoxin 1 (1.6) 
Aminophylline 1 (1.6) 
Ciprofloxacin+Aminophylline 1 (1.6) 
Methyldopa+Furosemide 1 (1.6) 
New drug started:   
Lisinopril+Furosemide 1 (1.6) 
 
Table 5: Outcome of intervention 
Variables n (%) 
Outcome of intervention unknown 49 (76.6) 
Problem totally solved  2 (3.1) 
Problem partially solved 10 (15.6) 
No need or possibility to solve problem 3 (4.7) 
 
Table 6: Association between intervention and institution 
  Institution      
UNTH Medical centre Total χ2 df P-value 
Intervention Yes 14 2 16 6.323 1 **0.012 
 No 25 23 48    
 Total 39 25 64    
Phi =-0.314 
 
Table 7: Association between “outcome of intervention” and institution 
  Institution      
  UNTH Medical Centre Total χ2 df P-value 
Known Outcome of Intervention Yes 15 0 15 12.559 1 **<0.001 
 No 24 25 49    




In this study, a total of 53 drug therapy problems (DTPs) were identified 
among asthmatic patients receiving care over the past 15 y. Other 
studies have identified similar DTPs. Khan et al. [8] identified 91 DTPs in 
80 asthmatics patients, Nascimento et al. [9] identified 380 DTPs in a 
period of two years, Root et al. [10] identified 88 DTPs from 40 patients. 
The difference in the number of DTPs encountered is probably due to 
differences in research design in terms of patients’ type, hospital types, 
duration of the studies and nature of data collected. 
Various drug combinations were responsible for DTPs which may 
have resulted to therapy failure or adverse drug reactions. The use 
of artemether-lumefantrine with vitamin c and aminophylline with 
hydrocortisone constituted the major drug therapy problems in this 
study. Ganiyu et al. [11] demonstrated in vivo ascorbic acid impairs 
the activity of artemether in the clearance of Plasmodium berghei. 
Aminophylline and hydrocortisone drug combinations could lead to 
increased plasma concentration of aminophylline by the 
hydrocortisone. This is supported by a study conducted in Italy on 
the effects of hydrocortisone and aminophylline on the aggregation 
of equine platelets in vitro [12].  
Majority of the identified DTPs were due to adverse reactions 
(65.7%). Most of the respondents were below 60 y of age, female 
and taking more than two medications. This is line with the study by 
Vervolet and Durham which concluded that adverse drug reactions 
occur mainly in young and middle-aged adults and are twice 
common in women [13]. Also, the use of multiple medications 
predisposes patients to adverse drug reactions [14]. Most of the 
patients in this study were on more than seven drugs. Some of these 
medications may also predispose the patients to other disease states 
as a study showed that the duration of therapy with beta-2 agonists 
positively correlated with the incidence of hypertension [15]. 
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Our findings establish that inappropriate drug combinations were 
the major cause of drug therapy problems. This contrasts that 
obtained in a study on asthma therapy-related problems in adult 
Mediterranean Croatian patients were about 40% of the drug 
therapy problems were due to non-adherence to medication (66%) 
[16]. However, in another study by Khan et al., most DTPs (48.75%) 
were from potential drug interactions [8]. Patients’ poor knowledge 
on asthma and unfavorable attitudes towards their disease might 
also be responsible for undesirable drug interactions, especially 
with over-the-counter drugs [17]. Pharmacists can help in the right 
choice of drugs and possible combinations. Their counselling can 
improve patient adherence and the outcome of therapy [18].  
Inappropriate drug selection and combination were the major 
causes of DTPs in this study which is consistent with a number other 
studies [19, 20-22]. Inappropriate drug selection may be due to 
inappropriate prescribing. Inappropriate prescribing may lead to 
increased asthma-related deaths which are totally preventable. 
Asthma patients in UK were at risk of a potentially life-threatening 
asthma attack due to unsafe prescribing [22]. 
About three-quarter of the DTPs had no documented interventions 
which might have stemmed from poor attitudes to documentation and 
poor patient-care approach. Of the few interventions documented, 
only a quarter had known intervention outcomes. Poor drug history 
documentation may lead to medication errors [23]. Health 
professionals should document appropriately to minimize or eliminate 
medication errors. Pharmacists’ participation in medication history 
documentation might significantly increase the frequency and depth of 
medication history information documented [24]. UNTH had more 
interventions and known outcomes of interventions than Medical 
Centre. This may be because UNTH is a tertiary hospital, has a 
respiratory clinic, consultant pulmonologists and registrars with 
perhaps, better management and documentation protocols. 
Our study had some limitations. The approach used to identify and 
classify DTPs was based on a review of medical records. Thus, there 
was no direct contact with the asthmatic patients. Also, due to 
improper or lack of documentation, few folders were pulled out for 
the study. Some of the patients’ folders that were made available 
lacked sufficient information. These might have limited the 
information obtained. 
We recommend that physicians and other healthcare providers 
should ensure proper asthma care to avoid therapy problems and 
complications. They should adhere to the recommended guidelines 
and utilize reference books to minimize errors in prescription, 
dispensing or administration. Patients should be effectively 
counselled to ensure that they fully understand how and when to 
take their medications.  
Proper documentation system in health institutions should be 
encouraged. Physicians should improve in documenting on patients’ 
folders. This could be helpful for references and research. More 
professional librarians should be employed in Medical Records for 
expert documentation and easy assessment of files when needed. 
More studies on drug therapy problems in asthma should be 
conducted in Nigeria as there is a paucity of data. 
CONCLUSION 
Adverse reactions were identified as the drug therapy problems 
among asthmatics. Inappropriate drug selection was the major cause 
of drug therapy problems. Most of the DTPs had no interventions. 
The documented interventions included stopping of the drugs, 
change of drugs or dosage, change of instructions for use and 
starting of new drugs. The outcomes of most of the interventions 
were not known. UNTH had more interventions with known 
outcomes than the University of Nigeria Medical Centre. 
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